| Ytd | 34.94% | |
| 1y | 23.54% |
| Open | 9.88 | Prev Close | 9.90 | Low | 9.78 | High | 10.48 | Mkt Cap | 296.95M |
| Vol | 166.24K | Avg Vol | 272.92K | EPS | -0.23 | P/E | -45.17 | Forward P/E | 16.78 |
| Beta | 1.07 | Short Ratio | 13.06 | Inst. Own | 54.70% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 9.67 | 200-d Avg | 8.20 | 1yr Est | 13.60 |
FENC News
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Fennec Pharmaceuticals (NASDAQ:FENC)
Wedbush analyst David Nierengarten reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Outperf
~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK® in AYA & Adult
Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.17) per share which missed the
Fennec Pharmaceuticals (FENC) to release Q4 earnings on March 24. Analysts expect EPS of $0.04 and r
Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today announ
Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today announ
Piper Sandler analyst David Amsellem initiates coverage on Fennec Pharmaceuticals (NASDAQ:FENC) w
Pedmark cut cisplatin-related hearing loss in a Japan trial, with strong safety and no impact on tum
Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss
Fennec intends to use the net proceeds of the offering to repurchase and redeem certain indebtedness
Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.02) per share which met the an
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) ("Fennec" or the "Company"), a s
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fennec Pharmaceuticals (NASDAQ:FENC
Craig-Hallum analyst Chase Knickerbocker maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Bu
Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.11) per share which missed the
On Wednesday, 311 stocks hit new 52-week lows.